🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ShapeTX scientist Lina Bagepalli designs guide RNAs for efficient and specific RNA editing to correct genetic mutations that cause disease. See how Lina's scientific work mirrors her artistic process, finding the balance between control and experimentation bit.ly/3MfphnL

There's been a big milestone in the therapeutics community - we're thrilled to see the UK approval of the first CRISPR medicine, and we look forward to the day the first RNA editing therapy is approved for treating genetic diseases! bit.ly/40FterM

ShapeTX CTO Adrian Briggs has always been drawn to solving seemingly insurmountable scientific problems. Learn how Adrian's scientific journey has brought him to leading a team that is creating disruptive end-to-end gene therapies in his employee spotlight bit.ly/3ukpeAV

2023 was a meaningful year for the cell and gene therapeutics industry, and we were proud to announce our partnership with Otsuka. We look forward to continued industry growth in 2024: bit.ly/3ujAX2K

We've expanded our work with Roche to add a new target to our existing collaboration. For this partnership, we're conducting preclinical research to identify and deliver development candidates discovered by our AI-powered RNAfix™ platform: bit.ly/46DGwql

ICYMI - we've expanded our partnership with Roche to add an additional target by utilizing our AI-powered RNAfix™ platform. Read the latest on this deal and our Otsuka deal from earlier this year via FierceBiotech: bit.ly/3R1l4pw

On the anniversary of ChatGPT's launch, Fast Company asked asked AI leaders including our SVP and Head of AI Ron Hause how #generativeAI is changing drug development. Read their insights here: bit.ly/3RoUA2s

Our SVP and Head of AI Ron Hause leads a team using #generativeAI to develop programmable RNA medicines for disease treatment. What does that mean in practice? Check out Ron's Coworking feature in Tech Brew ☕ to learn more bit.ly/3uDWCmD

As this year comes to a close, we're looking back on some of our proudest moments from 2023. In May, our CSO David Huss was named one of Endpoints News 20 under 40 in Biopharma. We're proud of David's ShapeTX accomplishments while also running 100+ mile races! bit.ly/48rrDbM

Looking back on our proudest moments of 2023, our SVP and Head of AI Ron Hause's byline in Fast Company is on our list! Read about how biotechs like ShapeTX are expanding the possibilities of generative AI for the next generation of drug development here: bit.ly/42XaFPC

We’ve enjoyed many great successes in 2023 thanks to our partners. In fall we announced our collaboration w/ Otsuka to apply our generative AI and AAVid™ capsid discovery platform w/ Otsuka’s expertise in ocular diseases to create novel treatment options bit.ly/3ZjG1je

Our latest news update was an expansion of our partnership with Roche. In December, Roche added an additional target by utilizing our AI-powered RNAfix™ platform. A great way to close out 2023! Read about this and other ShapeTX news via FierceBiotech bit.ly/3R1l4pw

Calling all JPM Healthcare Conference attendees - join our VP of Process and Product Development, Ken Prentice as he moderates a panel on next-generation gene therapy for GenScript's Biotech Global Forum on Jan 10 at 3:20 PM! Tickets available here: bit.ly/3S6yu4b

Heading to #JPM2024 next week? Meet with us onsite to learn more about our work creating programmable medicines with AI and RNA! Reach out via our contact form to set up a meeting: bit.ly/47mT99A

ShapeTX is once again taking over Union Square for #JPM2024! Look out for our kiosk ads throughout the area and visit ShapeTX.com to learn more about our work in engineering programmable medicines!

Very exciting news from the recent ASGCT meeting! globenewswire.com/en/news-releas…

Lessons from Shape Therapeutics: How to harness AI for R&D success benchling.com/blog/lessons-f…

We are pleased to welcome David Epstein and Todd Simpson to our board of directors. Their collective experience and expertise will be invaluable as we continue to advance our transformative science and drive growth. globenewswire.com/news-release/2…

How do you turn AI conversations into real progress? Next week at Benchtalk 2024, Generate’s Tharindi H, PhD, joins Will Weiss of Eli Lilly and Company and Ron Hause from ShapeTX Inc. to discuss R&D’s toughest challenges. Don’t miss out—details here: benchtalk.benchling.com/boston24

Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA edits. biotechtv.com/post/shape-the…